Skip to main content
Caplight Logo









Auron Therapeutics

Auron Therapeutics

Private
Newton, MassachusettsHealthcare & Life Scienceshttps://www.aurontx.com/

Last Round

Seed Round

Aug 13, 2026

Est. Valuation

$158M

Total Funding Raised

$87.75M

Company Overview

Auron Therapeutics is a biotechnology company that develops targeted small molecule therapies by analyzing dysfunctional cell states to treat cancers and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biotechnologydrug discoveryoncologydifferentiation therapysmall-molecule therapycell-state plasticityprotein degraderAI drug discoveryprecision medicinemulti-omic datasetsbiomarker identificationin silico drug discoverycomputational biologyclinical-stage biotechtargeted therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Auron Therapeutics Comparables

Compare Auron Therapeutics with similar companies based on industry and business-model similarity.

Auron Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Noetik
76%
StemGen S.p.A.
75%
Accent Therapeutics
74%

Auron Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundAug 13, 2026
Series BFeb 4, 2025
Series AJul 20, 2022
SeedJan 27, 2021

Key People

Founding team and executive leadership

Glenn Goddard

Chief Financial Officer

Executive Team

Auron Therapeutics Investors

Notable investors and investment history

Auron Therapeutics investors
InvestorRounds
Apollo VenturesSeries B, Series A
DCVC BioSeries B, Series A
BrightEdgeSeries B, Series A, Seed
BrightEdgeSeries B, Series A, Seed
Arkin HoldingsSeries B, Series A
Mubadala CapitalSeries B, Series A
QimingSeries B, Series A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 13, 2026

    Raised $7.1M in Seed funding.

  • Oct 13, 2025

    Will attend the 8th Annual Targeted Protein Degradation & Induced Proximity Summit.

Auron Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Auron Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Auron Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNewton, Massachusetts
Employee Range21
Year Founded2018
Last FundingAug 13, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?